Mabwell Bioscience-B (02493.HK) achieved operating revenue of approximately RMB 621 million in the first three quarters, up 9.77% year on year.

Zhitong Finance APP News, Mabwell Biotech-B (02493.HK) announced its results for the first three quarters of 2026, with operating revenue of approximately RMB 621 million, a year-on-year increase of 9.77%; net loss attributable to shareholders of the listed company of approximately RMB 678 million, and basic loss per share of RMB 1.6.